Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2132489 | 0.88 | KMT2A (0.60) | KMT2ACYP1A2CYP2C9CYP2C19MEN1 | |
| SCHEMBL13431153 | 0.86 | KMT2A (0.46) | KMT2ACYP1A2CYP2C9CYP2C19MEN1 | |
| SCHEMBL31265674 | 0.79 | ALDH1A1 (0.55) | KMT2ACYP1A2CYP2C9CYP2C19MEN1 | |
| SCHEMBL14294953 | 0.79 | KMT2A (0.53) | KMT2ACYP1A2CYP2C9CYP2C19MEN1 | |
| SCHEMBL3278731 | 0.79 | ALDH1A1 (0.55) | KMT2ACYP1A2CYP2C9CYP2C19MEN1 | |
| SCHEMBL16875050 | 0.78 | KMT2A (0.51) | KMT2ACYP1A2CYP2C9CYP2C19MEN1 | |
| SCHEMBL13283451 | 0.77 | KMT2A (0.40) | KMT2ACYP1A2CYP2C9CYP2C19MEN1 | |
| SCHEMBL1939642 | 0.77 | NPSR1 (0.44) | KMT2ACYP1A2CYP2C9CYP2C19MEN1 | |
| SCHEMBL15806324 | 0.76 | RXFP1 (0.42) | KMT2ACYP1A2CYP2C9CYP2C19MEN1 | |
| SCHEMBL11826738 | 0.75 | KDM4E (0.48) | KMT2ACYP1A2CYP2C9CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872507-A1 | AZAINDOLE DERIVATIVES WHICH ACT AS PI3K INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-20140343033-A1 | AZAINDOLE DERIVATIVES | Takeda Califomia, Inc. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8835420-B2 | Azaindole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-16 | — | — | US | disclosed |
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2014011568-A1 | AZAINDOLE DERIVATIVES WHICH ACT AS PI3K INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-16 | — | — | WO | disclosed |
| US-20140018344-A1 | AZAINDOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-16 | — | — | US | disclosed |
| EP-2665725-A1 | BICYCLIC INHIBITORS OF ALK | AbbVie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| EP-2330909-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8383635-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383635-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-02-26 | — | — | US | disclosed |
| WO-2012097683-A1 | BICYCLIC INHIBITORS OF ALK | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012097683-A1 | BICYCLIC INHIBITORS OF ALK | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| EP-2330909-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20110136838-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110136838-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110136838-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-06-09 | — | — | US | disclosed |
| WO-2010019637-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019637-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343033-A1 | AZAINDOLE DERIVATIVES | PIK3R5, PIK3R1, PIK3R2 | KMT2A 2404/4885CYP1A2 600/4885CYP2C9 208/4885 |
| US-20110136838-A1 | CHEMICAL COMPOUNDS | PDK1, PDK4, PDK3 | KMT2A 1745/4885CYP1A2 1670/4885CYP2C9 2450/4885 |
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ACVR1, ACVR1B | KMT2A 593/4885CYP1A2 751/4885CYP2C9 1290/4885 |
| US-20140018344-A1 | AZAINDOLE DERIVATIVES | PIK3R5, PIK3R1, PIK3R2 | KMT2A 2404/4885CYP1A2 600/4885CYP2C9 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.